SCHEMBL6635018

SCHEMBL6635018

CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ccccc4C3)c(F)c2)C(=O)O1

nearest known ligand 0.74

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAOA P21397 6/20 0.74
MAOB P27338 5/20 0.74
PTGS1 P23219 2/20 0.74
SDHA P31040 2/20 0.74
LMNA P02545 1/20 0.74
CALML3 P27482 1/20 0.74
F10 P00742 5/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27535197 0.94 MAOA (0.71) MAOAMAOBPTGS1SDHALMNA
SCHEMBL6615781 0.91 MAOA (0.78) MAOAMAOBPTGS1SDHALMNA
SCHEMBL6615783 0.91 MAOA (0.78) MAOAMAOBPTGS1SDHALMNA
SCHEMBL6638114 0.89 MAOA (0.65) MAOAMAOBPTGS1SDHALMNA
SCHEMBL7815229 0.89 MAOA (0.75) MAOAMAOBPTGS1SDHALMNA
SCHEMBL7815231 0.89 MAOA (0.75) MAOAMAOBPTGS1SDHALMNA
SCHEMBL6635551 0.89 MAOA (0.67) MAOAMAOBPTGS1SDHALMNA
SCHEMBL14881430 0.89 MAOA (0.78) MAOAMAOBPTGS1SDHALMNA
SCHEMBL14881432 0.89 MAOA (0.78) MAOAMAOBPTGS1SDHALMNA
SCHEMBL6635207 0.88 MAOA (0.66) MAOAMAOBPTGS1SDHALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1330647-C Heterobicyclic substituted phenyl * oxazolidinone antibacterial agents ORTHO MCNELL PHARMACEUTICAL IN (US) 2007-08-08 CN disclosed
US-6770664-B2 PYRROLO(3,4-C)PYRAZOL-5(4H)-YL)-3-FLUOROPHENYL)-2-OXO-5 -OXAZOLIDINYL)METHYL)ACETAMIDE DERIVATIVES; BACTERICIDES AGAINST DRUG RESISTANT STAPHYLOCOCCUS, STREPTOCOCCUS, AND/OR ENTEROCOCCUS PAGET STEVEN D (US) 2004-08-03 US disclosed
US-20040067994-A1 BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS PAGET STEVEN D (US) 2004-04-08 US disclosed
EP-1206469-B1 ANTIBACTERIAL HETEROBICYCLIC SUBSTITUTED PHENYL OXAZOLIDINONES ORTHO MCNEIL PHARM INC (US) 2004-02-25 EP disclosed
US-20030171366-A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods PAGET STEVEN (US) 2003-09-11 US disclosed
US-6608081-B2 Treating pneumonia ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-08-19 US disclosed
US-20020161029-A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-10-31 US disclosed
US-6413981-B1 DRUG-RESISTANT GRAM POSITIVE AND GRAM NEGATIVE BACTERIA; PNEUMONIA; INFECTIONS OF UPPER AND LOWER RESPIRATORY TRACT, SKIN, SOFT TISSUE, BONES AND JOINTS ORTHO-MCNEIL PHARAMCEUTICAL, INC. 2002-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161029-A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods OXA1L, NDUFS3, CYCS MAOA 456/4885MAOB 395/4885PTGS1 2228/4885
US-20040067994-A1 BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS OXA1L, NDUFS3, CYCS MAOA 456/4885MAOB 395/4885PTGS1 2228/4885
US-20030171366-A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods OXA1L, NDUFS3, CYCS MAOA 443/4885MAOB 359/4885PTGS1 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.